journal
MENU ▼
Read by QxMD icon Read
search

Clinical Therapeutics

journal
https://www.readbyqxmd.com/read/28089200/limitations-of-the-current-standards-of-care-for-treating-gout-and-crystal-deposition-in-the-primary-care-setting-a-review
#1
Robert T Keenan
PURPOSE: This article outlines several important issues regarding the management of patients with gout. The topics discussed include best practices for gout based on the most current guidelines, opportunities for improving gout management, and current and emerging therapies for gout. METHODS: [PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]...
January 11, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28081848/ranolazine-and-microvascular-angina-by-pet-in-the-emergency-department-results-from-a-pilot-randomized-controlled-trial
#2
Basmah Safdar, Gail D'Onofrio, James Dziura, Raymond R Russell, Caitlin Johnson, Albert J Sinusas
PURPOSE: Coronary microvascular dysfunction (CMD) is a common but underdiagnosed cause of chest pain. Literature is scant regarding effective treatments. We explored the effect of ranolazine on coronary flow reserve (CFR) among symptomatic patients with CMD. METHODS: This pilot double-blinded randomized controlled trial included emergency department patients with chest pain and CMD admitted to an observation unit between June 2014 and November 2015. Participants were assessed by cardiac Rb-82 positron emission tomography and computed tomography imaging at baseline and 30 days...
January 9, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28069260/drugs-and-medical-devices-adverse-events-and-the-impact-on-women-s-health
#3
REVIEW
Jennifer L Carey, Nathalie Nader, Peter R Chai, Stephanie Carreiro, Matthew K Griswold, Katherine L Boyle
A large number of medications and medical devices removed from the market by the US Food and Drug Administration over the past 4 decades specifically posed greater health risks to women. This article reviews the historical background of sex and gender in clinical research policy and describes several approved drugs and devices targeted for use in women that have caused major morbidity and mortality. The intended population for the medications and devices, population affected, approval process, and the basic and legal actions taken against the medication/drug company are also discussed...
January 6, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28069259/sex-differences-in-hazard-ratio-during-drug-treatment-of-non-small-cell-lung-cancer-in-major-clinical-trials-a-focused-data-review-and-meta-analysis
#4
Lishi Wang, Yanhong Cao, Mingji Ren, Amei Chen, Jinglin Cui, DiaJun Sun, Weikuan Gu
PURPOSE: Understanding how sex impacts the efficacy of anticancer agents is a crucial step toward personalized and precision medicine. This review and meta-analysis evaluated sex differences in hazard ratios (HRs) of progression-free survival and overall survival in representative Phase III clinical trials of non-small-cell lung cancer (NSCLC). METHODS: Data were extracted from 24 large-scale clinical trials that included 12,000 male and 7000 female patients. The data were examined for HR differences between subgroups by sex, smoking status, and age, and for potential sex-smoking status, sex-age, and sex-drug interactions, during cancer treatment...
January 6, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28065438/using-health-care-claims-data-to-assess-the-prevalence-of-hodgkin-lymphoma-and-relapsed-or-refractory-hodgkin-lymphoma-in-the-united-states
#5
Jay Lin, Lisa R Siegartel, Melissa Lingohr-Smith, Brandy Menges, Dinara Makenbaeva
PURPOSE: Although most patients with Hodgkin lymphoma (HL) respond to primary therapy, some patients experience relapses or are refractory to treatment (RR-HL). The objectives of this study were to investigate the prevalence of HL and RR-HL in the United States by using a large health care claims database. METHODS: Patients with ≥1 diagnosis for HL between January 1, 2013, and September 30, 2014 (prevalence assessment period), in the MarketScan Commercial and Medicare databases were identified...
January 5, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28062114/effect-of-immediate-administration-of-antibiotics-in-patients-with-sepsis-in-tertiary-care-a-systematic-review-and-meta-analysis
#6
REVIEW
Amy N B Johnston, Joon Park, Suhail A Doi, Vicki Sharman, Justin Clark, Jemma Robinson, Julia Crilly
PURPOSE: The goal of this review was to synthesize existing evidence regarding outcomes (mortality) for patients who present to the emergency department, are administered antibiotics immediately (within 1 hour) or later (>1 hour), and are diagnosed with sepsis. METHODS: A search of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and CINAHL, using the MeSH descriptors "sepsis," "systemic inflammatory response syndrome," "mortality," "emergency," and "antibiotics," was performed to identify studies reporting time to antibiotic administration and mortality outcome in patients with sepsis...
January 3, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28062113/indirect-treatment-comparisons-of-ibrutinib-versus-physician-s-choice-and-idelalisib-plus-ofatumumab-in-patients-with-previously-treated-chronic-lymphocytic-leukemia
#7
REVIEW
Sonja Sorensen, Mark Wildgust, Nishan Sengupta, Cristina Trambitas, Joris Diels, Suzy van Sanden, Yingxin Xu, Emily Dorman
PURPOSE: Treatment options for patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) are limited. Until recently, few effective treatment options existed, and even with the advent of new agents, studies evaluating comparative efficacy are scarce. In the Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE) Phase III study, ibrutinib, an oral, once-a-day, first-in-class covalent Bruton tyrosine kinase inhibitor, improved progression-free survival (PFS) and overall survival (OS) compared with ofatumumab (PFS hazard ratio [HR] = 0...
January 3, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28038791/combination-therapy-with-vancomycin-and-ceftaroline-for-refractory-methicillin-resistant-staphylococcus-aureus-bacteremia-a-case-series
#8
Diana Gritsenko, Marianna Fedorenko, Jorg J Ruhe, Jerry Altshuler
PURPOSE: Although vancomycin has been the mainstay of therapy for methicillin-resistant Staphylococcus aureus (MRSA) infections, its effectiveness has been challenged. Combination therapy may be used for patients with persistent MRSA bacteremia refractory to initial therapy. Studies have reported in vitro synergy between vancomycin and ceftaroline; however, clinical experience with this therapy is limited. Here, we report our experience with 5 cases of vancomycin-refractory MRSA bacteremia treated with the combination of vancomycin and ceftaroline...
December 27, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28034521/2017-sexual-dimorphism-sexual-pluralism-and-more
#9
EDITORIAL
Richard I Shader
No abstract text is available yet for this article.
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28034520/the-effects-of-sex-and-gender-on-pharmacologic-toxicity-implications-for-clinical-therapy
#10
EDITORIAL
Alyson J McGregor
No abstract text is available yet for this article.
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28034519/treatment-outcomes-in-infections-caused-by-spice-serratia-pseudomonas-indole-positive-proteus-citrobacter-and-enterobacter-organisms-carbapenem-versus-noncarbapenem-regimens
#11
Stanley Moy, Roopali Sharma
PURPOSE: Techniques used to identify AmpC β-lactamases in SPICE (Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter) organisms are not yet optimized for the clinical laboratory and are not routinely used. Clinicians are often left with an uncertainty on the choice of antibiotic when a SPICE organism is isolated. The purpose of this study was to evaluate the outcomes of carbapenem versus noncarbapenem regimens in treating bacteremia or urinary tract infection from a SPICE organism in clinical practice...
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28034518/sex-effect-on-average-bioequivalence
#12
Manuel Ibarra, Marta Vázquez, Pietro Fagiolino
PURPOSE: Generic formulations are by far the most prescribed drugs. This scenario is highly beneficial for society because medication expenses are significantly reduced after expiration of the exclusivity period conceded to the branded name drug. Correspondingly, these formulations must be adequately evaluated to avoid drug inefficacy and toxicity in the overall patient population. Bioequivalence studies are the only in vivo evaluation that a generic drug must overcome to reach the market...
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28034517/impact-of-paradoxical-decrease-in-high-density-lipoprotein-cholesterol-levels-after-statin-therapy-on-major-adverse-cardiovascular-events-in-patients-with-stable-angina-pectoris
#13
Kenshi Hirayama, Tomoyuki Ota, Kazuhiro Harada, Yohei Shibata, Yosuke Tatami, Shingo Harata, Kazuhiro Kawashima, Ayako Kunimura, Yusaku Shimbo, Yohei Takayama, Toshiki Kawamiya, Dai Yamamoto, Naohiro Osugi, Susumu Suzuki, Hideki Ishii, Toyoaki Murohara
PURPOSE: Statin therapy usually increases HDL-C levels. However, a paradoxical decrease in HDL-C levels after statin therapy is often seen in clinical settings. The relationship between a paradoxical decrease in HDL-C levels after statin therapy and adverse cardiovascular events in patients with stable angina pectoris (SAP) is not well understood. The purpose of this study was to analyze the relationship between paradoxical HDL-C decreases after statin therapy and major adverse cardiovascular events (MACEs) in patients undergoing percutaneous coronary intervention (PCI) for SAP...
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28012569/efficacy-of-methylprednisolone-acetate-versus-triamcinolone-acetonide-intra-articular-knee-injection-in-patients-with-chronic-inflammatory-arthritis-a-24-week-randomized-controlled-trial
#14
Ashwani Kumar, Varun Dhir, Shefali Sharma, Aman Sharma, Surjit Singh
PURPOSE: Triamcinolone hexacetonide (TH), triamcinolone acetonide (TA), and methylprednisolone acetate (MPA) are commonly used intra-articular steroid preparations. Studies suggest that intra-articular TH is more efficacious than MPA and TA in chronic inflammatory arthritis. However, it is unclear which of the latter two preparations has better efficacy. Thus, we compared intra-articular knee injections of MPA and TA in patients with chronic inflammatory arthritis. METHODS: This double-blind, randomized controlled trial included patients with rheumatoid arthritis or spondyloarthritis with an acutely swollen knee joint (≥1 week, <24 weeks)...
December 21, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28011248/different-disclosed-probabilities-to-receive-an-antiemetic-equally-decrease-subjective-symptoms-in-an-experimental-placebo-study-to-be-or-not-to-be-sure
#15
Katja Weimer, Björn Horing, Eric R Muth, Jenna L Scisco, Sibylle Klosterhalfen, Paul Enck
PURPOSE: The purpose of this study was to examine whether the disclosed probability of receiving an antiemetic affects nausea. METHODS: Forty-eight healthy participants (mean [SD] age, 26.8 [5.4] years; 50% female) were exposed to 5 × 2 minutes of nauseogenic body rotations on 2 days. On day 2, participants were randomized to 3 experimental groups that were given different instructions concerning the probability of receiving an antiemetic remedy (100%, 50%, or 0% probability), whereas all received an inert substance...
December 20, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28011247/health-status-of-patients-with-moderate-to-severe-copd-after-treatment-with-nebulized-arformoterol-tartrate-or-placebo-for-1-year
#16
James F Donohue, Vaidyanathan Ganapathy, Vamsi Bollu, Michael D Stensland, Lauren M Nelson
PURPOSE: Chronic obstructive pulmonary disease (COPD) is a progressive disease that impairs both objectively measured lung function and patient-reported health status. In a randomized clinical trial of patients with moderate to severe COPD, we compared changes in health status after adding arformoterol tartrate or placebo to patients' treatment regimens. METHODS: In this multicenter, double-blind trial, patients were randomized to receive nebulized arformoterol 15 µg BID (n = 420) or matched placebo (n = 421)...
December 20, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28007332/predictive-modeling-of-response-to-pregabalin-for-the-treatment-of-neuropathic-pain-using-6-week-observational-data-a-spectrum-of-modern-analytics-applications
#17
Birol Emir, Kjell Johnson, Max Kuhn, Bruce Parsons
PURPOSE: This post hoc analysis used 11 predictive models of data from a large observational study in Germany to evaluate potential predictors of achieving at least 50% pain reduction by week 6 after treatment initiation (50% pain response) with pregabalin (150-600 mg/d) in patients with neuropathic pain (NeP). METHODS: The potential predictors evaluated included baseline demographic and clinical characteristics, such as patient-reported pain severity (0 [no pain] to 10 [worst possible pain]) and pain-related sleep disturbance scores (0 [sleep not impaired] to 10 [severely impaired sleep]) that were collected during clinic visits (baseline and weeks 1, 3, and 6)...
December 19, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28007331/combination-therapy-of-rosuvastatin-and-ezetimibe-in-patients-with-high-cardiovascular-risk
#18
Young-June Yang, Sang-Hak Lee, Byung Soo Kim, Yun-Kyeong Cho, Hyun-Jai Cho, Kyoung Im Cho, Seok-Yeon Kim, Jae Kean Ryu, Jin-Man Cho, Joong-Il Park, Jong-Seon Park, Chang Gyu Park, Woo Jung Chun, Myung-A Kim, Dong-Kyu Jin, Namho Lee, Byung Jin Kim, Kwang Kon Koh, Jon Suh, Seung-Hwan Lee, Byoung-Kwon Lee, Seung-Jin Oh, Han-Young Jin, Youngkeun Ahn, Sang-Gon Lee, Jang-Ho Bae, Woo Jung Park, Sang-Chol Lee, Han Cheol Lee, Jaewon Lee, Cheolwon Park, Backhwan Lee, Yangsoo Jang
PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk. METHODS: This was a 12-week, randomized, double-blind, placebo-controlled, multicenter study. A total of 337 patients were screened. After a 4-week run-in period, 245 of these patients with high or moderately high risk as defined by the National Cholesterol Education Program Adult Treatment Panel III guidelines were randomly assigned...
December 19, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27989619/determinants-of-treatment-eligibility-in-veterans-with-hepatitis-c-viral-infection
#19
Janice Taylor, Sian Carr-Lopez, Amy Robinson, Robert Malmstrom, Karsten Duncan, Archana Maniar, A C Del Re, Jannet M Carmichael
PURPOSES: The objective of this study was to determine the percentage of veterans with active hepatitis C virus (HCV) infection who were deemed to be candidates for treatment and to identify factors associated with treatment ineligibility. METHODS: This was a multisite, retrospective cohort analysis of veterans with HCV infection within the Veteran Integrated Service Network 21. Patients evaluated between August and November 2015 who were viremic and not receiving HCV treatment were included in the analysis...
December 15, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27989618/pharmacokinetic-interactions-between-pelubiprofen-and-eperisone-hydrochloride-a-randomized-open-label-crossover-study-of-healthy-korean-men
#20
Ju-Hee Ryu, Joo-Il Kim, Hyung Son Kim, Gyu-Jeong Noh, Kyung-Tae Lee, Eun Kyoung Chung
PURPOSE: Pelubiprofen is a novel nonsteroidal anti-inflammatory, analgesic, and antipyretic drug with at least similar efficacy and better tolerability compared with other nonsteroidal anti-inflammatory, analgesic, and antipyretic drugs such as naproxen and aceclofenac. Eperisone hydrochloride is a centrally acting muscle relaxant that performs by blocking calcium channels. The combined use of pelubiprofen and eperisone hydrochloride is increasingly anticipated to promote the clinical effectiveness of pelubiprofen in relieving musculoskeletal symptoms of osteoarthritis, rheumatoid arthritis, and low back pain...
December 15, 2016: Clinical Therapeutics
journal
journal
27126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"